NEUROENDOCRINE CARCINOMA
Clinical trials for NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo enters human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing whether a new combination of two drugs, ZG006 and ZG005, is safe and effective for people with advanced small cell lung cancer or neuroendocrine carcinoma. It will involve about 350 adult participants to see if the drug combo can shrink tumors and control th…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for tough cancers: early trial tests ZG006 drug
Disease control Recruiting nowThis early-stage study is testing a new drug called ZG006 for people with advanced small cell lung cancer or neuroendocrine carcinoma who have no standard treatments left or cannot tolerate them. The main goals are to find a safe dose, check for side effects, and see if the drug …
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Trial pitches Triple-Threat chemo against rare, Fast-Moving cancer
Disease control Recruiting nowThis study is testing if a more intensive, three-drug chemotherapy regimen (mFOLFIRINOX) works better than the current standard two-drug treatment for people with a rare, fast-growing type of digestive cancer that has spread. Researchers will also analyze tumor samples to underst…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for rare cancers: trial tests immune drug vs. chemo
Disease control Recruiting nowThis study is testing if an immunotherapy drug called dostarlimab works better than standard chemotherapy as a first treatment for adults with certain rare, advanced cancers that have spread or cannot be surgically removed. About 120 participants will be randomly assigned to rece…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New oral cancer pill enters first human trials for Tough-to-Treat tumors
Disease control Recruiting nowThis is the first study in people to test a new oral medication called CID-078 for advanced solid tumors. The main goals are to find a safe dose and see how well the body handles the drug. The study will enroll adults with cancers like triple-negative breast cancer, small cell lu…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE1 • Sponsor: Circle Pharma • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug trial offers hope for Tough-to-Treat neuroendocrine cancer
Disease control Recruiting nowThis Phase 3 trial is testing whether an experimental drug called tarlatamab works better than standard chemotherapy for people with advanced neuroendocrine carcinoma that has worsened after initial treatment. The study will enroll 129 adults whose cancer has spread and who have …
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
Cancer-Fighting virus teams up with immunotherapy in new trial
Disease control Recruiting nowThis early-stage trial is testing a new combination treatment for patients with advanced neuroendocrine tumors that have progressed after standard therapy. Researchers are combining an experimental virus designed to attack cancer cells (SVV-001) with two established immunotherapy…
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE1 • Sponsor: Peter Hosein, MD • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Your genes could dictate your cancer drug dose
Disease control Recruiting nowThis study is testing whether adjusting the dose of a cancer drug (belinostat) based on a patient's specific genetics can make treatment safer and more effective. It is for adults with aggressive neuroendocrine cancers. Participants receive a combination of three drugs, with the …
Matched conditions: NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC